Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Teicoplanin

Generic name
Teicoplanin
Brand name
ATC Code
J01XA02

Pharmacokinetics in children

When administered orally Teicoplanin is not absorbed from gastrointestinal tract [SmPC].

The studies by Reed et al. and Dufort et al. show that the clearance of teicoplanin in children younger than 12 years is higher than in adults. Clearance in children aged < 12 years is very variable; range 29-51 ml/hour/kg.

Lukas et al. suggest that teicoplanin in children < 1 year (N = 4) possibly has a lower clearance and volume of distribution than in children: > 1 year (N = 16). These values in children aged < 1 year are 0.09 l/hour and 1.05 litres respectively. In children aged > 1 year, these values are 0.29 l/hour and 3.9 litres respectively.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Bacterial infections
  • Intravenous
    • 1 month up to 2 months
      • Initial dose: 16 mg/kg/day in 1 dose
      • Maintenance dose: 8 mg/kg/day in 1 dose
    • 2 months up to 12 years
      • Initial dose: 10 mg/kg/dose every 12 hours for the first 3 doses.
      • Maintenance dose: 6 - 10 mg/kg/day in 1 dose
    • Term neonate
      • Initial dose: 16 mg/kg/day in 1 dose
      • Maintenance dose: 8 mg/kg/day in 1 dose
Clostridium difficile infection
  • Oral
    • ≥ 12 years
      • 200 - 400 mg/day in 2 doses.
      • Duration of treatment:

        7-14 days

    • ≥ 12 years
      • 200 - 400 mg/day in 2 doses.
      • Duration of treatment:

        7-14 days
Therapeutic Drug Monitoring (TDM) directive
  • Route of administration not applicable
    • 0 years up to 18 years

      • Serum concentration: First through level before first maintenance dose, after 3-4 days of maintenance therapy and after every dose adjustment and weekly until steady state. 

        Target trough level: 

        Complicated infections of skin and soft tissue, pneumonia and complicated urinart tract infections ≥ 15 mg/L
        Bone and joint infections, Intensive care patients and patients with burns ≥ 20 mg/L
        Infectious endocarditis ≥ 30 mg/L

         

         

         

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

GFR 50-80 ml/min/1.73 m2
Dose adjustment is not required

GFR 30-50 ml/min/1.73 m2
Day 1: no dose adjustment: normal starting dose (1st and 2nd dose of the starting dose series): 
Day 2: no dose adjustment: normal starting dose (3rd dose of the starting dose series).
Day 3: no dosage adjustment: normal maintenance dosage 
Day 4: 50% of normal maintenance dose once daily

GFR 10-30 ml/min/1.73 m2
Day 1: no dose adjustment: normal starting dose (1st and 2nd dose of the starting dose series): 
Day 2: no dose adjustment: normal starting dose (3rd dose of the starting dose series).
Day 3: no dosage adjustment: normal maintenance dosage 
Day 4: 33% of normal maintenance dose once daily

GFR < 10 ml/min/1.73 m2
A general recommendation cannot be given. A trade-off between the intended effect, the risks of side effects in case of overdose and therapy failure in case of underdose must be made for each patient.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Pain at the injection site, thrombophlebitis, allergic reactions, haematological reactions.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Teicoplanin is a ‘reserves’ antimicrobial drug and should only be prescribed after consulting an infectiologist/bacteriologist. Caution is needed in cases of hypersensitivity to vancomycin. In long-term use, in renal insufficiency and in simultaneous treatment with neurotoxic or nephrotoxic drugs it is recommended that the blood, liver, kidney and hearing functions should be checked regularly.
A case of a complete atrioventricular blockage has been described [Sharif-Yakan 2013]

 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Glycopeptide antibacterials
J01XA04
J01XA01
Polymyxins
J01XB01
Steroid antibacterials
J01XC01
Nitrofuran derivatives
J01XE01
Other antibacterials
J01XX09
J01XX08
J01XX01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Degraeuwe PL, et al, Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis., Biol Neonate, 1998, 73, 287-94
  2. Dufort G, et al, Teicoplanin pharmacokinetics in pediatric patients., Pediatr Infect Dis J, 1996, 15, 494-8
  3. Fanos V, et al, A review of teicoplanin in the treatment of serious neonatal infections, Eur J Pediatr, 1997, 156, 423-7
  4. Lukas JC, et al, Pharmacokinetics of teicoplanin in an ICU population of children and infants., Pharm Res, 2004, 21, 2064-71
  5. Möller JC, et al, Comparison of vancomycin and teicoplanin for prophylaxis of sepsis with coagulase negative staphylococci (CONS) in very low birth weight (VLBW) infants., J Perinat Med., 1997, 25, 361-7
  6. Reed MD, et al, The pharmacokinetics of teicoplanin in infants and children., J Antimicrob Chemother, 1997, 39, 789-96
  7. Tarral E, et al, Pharmacokinetics of teicoplanin in children., J Antimicrob Chemother., 1988, Jan;21 Suppl A, 47-51
  8. Yalaz M, et al, Experience with teicoplanin in the treatment of neonatal staphylococcal sepsis, J Int Med Res, 2004, 32, 540-8
  9. Sanofi-aventis Netherlands B.V, SmPC Targocid (RVG 13473) 02-05-2023, www.geneesmiddeleninformatiebank.nl
  10. Sharif-Yakan A et al., Complete heart block in a patient with acute lymphoblastic leukaemia: teicoplanin as a possible cause and review of literature, J Clin Pharm Ther, 2013, Apr;38(2), 156-8
  11. HEXAL®, SmPC Teicoplanin 100/200/400 mg Pulver zur Injektion (84895.00.00 / 84896.00.00 / 84897.00.00), 11/15
  12. Sanofi, SmPC Targocid 100/200/400 mg Pulver für Injektion (27257.00.00 / 27257.01.00 / 27257.02.00), 10/17

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes